AU2007215012A1 - Antibody formulation - Google Patents

Antibody formulation Download PDF

Info

Publication number
AU2007215012A1
AU2007215012A1 AU2007215012A AU2007215012A AU2007215012A1 AU 2007215012 A1 AU2007215012 A1 AU 2007215012A1 AU 2007215012 A AU2007215012 A AU 2007215012A AU 2007215012 A AU2007215012 A AU 2007215012A AU 2007215012 A1 AU2007215012 A1 AU 2007215012A1
Authority
AU
Australia
Prior art keywords
formulation
antibody
buffer
imc
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007215012A
Other languages
English (en)
Inventor
Joel Goldstein
Arvind Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of AU2007215012A1 publication Critical patent/AU2007215012A1/en
Assigned to IMCLONE LLC reassignment IMCLONE LLC Request for Assignment Assignors: IMCLONE SYSTEMS INCORPORATED
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2007215012A 2006-02-15 2007-02-15 Antibody formulation Abandoned AU2007215012A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77410106P 2006-02-15 2006-02-15
US60/774,101 2006-02-15
PCT/US2007/004050 WO2007095337A2 (en) 2006-02-15 2007-02-15 Antibody formulation

Publications (1)

Publication Number Publication Date
AU2007215012A1 true AU2007215012A1 (en) 2007-08-23

Family

ID=38372139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007215012A Abandoned AU2007215012A1 (en) 2006-02-15 2007-02-15 Antibody formulation

Country Status (13)

Country Link
US (1) US20090306348A1 (enExample)
EP (1) EP1987067A4 (enExample)
JP (1) JP2009526856A (enExample)
KR (1) KR20080096827A (enExample)
CN (1) CN101495136A (enExample)
AU (1) AU2007215012A1 (enExample)
BR (1) BRPI0707796A2 (enExample)
CA (1) CA2642270A1 (enExample)
EA (1) EA200870264A1 (enExample)
IL (1) IL193408A0 (enExample)
MX (1) MX2008010562A (enExample)
NO (1) NO20083640L (enExample)
WO (1) WO2007095337A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090021298A (ko) * 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
EP2527364A1 (en) 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP3011953A1 (en) * 2008-10-29 2016-04-27 Ablynx N.V. Stabilised formulations of single domain antigen binding molecules
EP2346900A1 (en) 2008-10-29 2011-07-27 Wyeth LLC Methods for purification of single domain antigen binding molecules
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
AU2011234264B2 (en) 2010-03-31 2016-02-04 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
US10206960B2 (en) 2010-03-31 2019-02-19 Stabilitech Biopharma Ltd Stabilisation of viral particles
HUE042330T2 (hu) 2010-03-31 2019-06-28 Stabilitech Biopharma Ltd Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
TWI486617B (zh) * 2010-10-21 2015-06-01 Iner Aec Executive Yuan 一種測定對鎝（Ｔｃ－９９ｍ）與錸（Ｒｅ－１８６、Ｒｅ－１８８）具有穩定錯合力之含硫螯合劑在凍晶劑中之含量與均一性的固態樣品分析技術
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
SG11201402661TA (en) * 2011-11-28 2014-08-28 Phasebio Pharmaceuticals Inc Therapeutic agents comprising insulin amino acid sequences
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
EP2830663B1 (en) * 2012-03-30 2019-02-06 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
AP2015008584A0 (en) 2013-02-08 2015-07-31 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
BR112018014150A2 (en) 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
CN106188296B (zh) * 2016-07-19 2018-05-08 康融东方（广东）医药有限公司 一类抗血管内皮生长因子受体vegfr2的单克隆抗体及其编码基因和应用
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
EP3684332A1 (en) * 2017-09-18 2020-07-29 Amgen Inc. Vegfr-fc fusion protein formulations
US12398209B2 (en) * 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
CN110646618B (zh) * 2019-09-17 2022-11-01 广州市伊川生物科技有限公司 一种c反应蛋白测定试剂盒及其制备方法和应用
CN114980926A (zh) * 2020-02-21 2022-08-30 江苏恒瑞医药股份有限公司 一种抗il-4r抗体药物组合物及其用途
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2003068259A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps

Also Published As

Publication number Publication date
IL193408A0 (en) 2011-08-01
BRPI0707796A2 (pt) 2011-05-10
KR20080096827A (ko) 2008-11-03
WO2007095337A2 (en) 2007-08-23
US20090306348A1 (en) 2009-12-10
MX2008010562A (es) 2009-03-05
CN101495136A (zh) 2009-07-29
CA2642270A1 (en) 2007-08-23
NO20083640L (no) 2008-11-17
EP1987067A2 (en) 2008-11-05
EP1987067A4 (en) 2012-01-25
EA200870264A1 (ru) 2009-02-27
WO2007095337A3 (en) 2008-11-27
JP2009526856A (ja) 2009-07-23

Similar Documents

Publication Publication Date Title
US20090306348A1 (en) Antibody Formulation
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
US20100158925A1 (en) Lyophilized formulations of anti-egfr antibodies
US20100260766A1 (en) Stable antibody formulations
TW201036650A (en) Lyophilised antibody formulation
CN112822999A (zh) Csf-1r抗体制剂
CN113194925B (zh) 抗体制剂
KR20220010483A (ko) 항-il17a 항체의 수성 약학적 조성물 및 이의 용도
KR20240141178A (ko) 이중특이적 항원-결합 분자 및 이의 용도
KR20220044286A (ko) 항 pd-1/her2 이중특이성 항체를 포함하는 제제, 이의 제조 방법 및 용도
JP2023529870A (ja) 抗体製剤希釈剤
CN116391041A (zh) 一种含抗结缔组织生长因子抗体的药物组合物
RU2829156C2 (ru) Композиция, содержащая анти-pd-1/her2 биспецифическое антитело, способ ее получения и ее использование
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
JP2025534054A (ja) 抗ｔｉｇｉｔ抗体を含む製剤及びその使用方法
KR20240167685A (ko) 항-Claudin18.2 및 CD3 이중특이성 항체를 포함하는 제제 및 이의 제조 방법과 용도
HK40057289B (zh) 抗体制剂
HK40057289A (en) Antibody formulations
HK40052133A (en) Csf-1r antibody formulation
HK40060532A (en) Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IMCLONE LLC

Free format text: FORMER APPLICANT(S): IMCLONE SYSTEMS INCORPORATED

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application